![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
Entry tags:
Novo Nordisk loses patent in Canada over drug that underlies Ozempic - over $450!
That's $450.00, as in I can pull that out of an ATM pretty much any time. Not $450 million. A little under five hundred bucks, and they lost their lock on their second largest market.
The Slashdot summary says it best:
"Pharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide -- the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- in Canada after failing to pay a $450 maintenance fee in 2019. The company had paid maintenance fees through 2018 but requested a refund for the 2017 fee, apparently seeking more time to decide whether to continue protecting the patent.
When the 2019 fee came due at $450 with late penalties, Novo never paid despite having a one-year grace period. Canadian patent authorities confirmed the patent "cannot be revived" once lapsed. The oversight is particularly costly given Canada represents the world's second-largest semaglutide market, worth billions annually. Generic drugmaker Sandoz plans to launch a competing version in early 2026, while Novo's U.S. patent protection extends until at least 2032.
WOW. That's certainly going to tarnish some board member's CV. But it's going to make a bunch of Canadian's a lot thinner!
https://www.science.org/content/blog-post/novo-nordisk-s-canadian-mistake
https://science.slashdot.org/story/25/06/16/1438211/novo-nordisk-loses-canadian-patent-protection-for-blockbuster-diabetes-drug-over-unpaid-450-fee
The Slashdot summary says it best:
"Pharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide -- the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- in Canada after failing to pay a $450 maintenance fee in 2019. The company had paid maintenance fees through 2018 but requested a refund for the 2017 fee, apparently seeking more time to decide whether to continue protecting the patent.
When the 2019 fee came due at $450 with late penalties, Novo never paid despite having a one-year grace period. Canadian patent authorities confirmed the patent "cannot be revived" once lapsed. The oversight is particularly costly given Canada represents the world's second-largest semaglutide market, worth billions annually. Generic drugmaker Sandoz plans to launch a competing version in early 2026, while Novo's U.S. patent protection extends until at least 2032.
WOW. That's certainly going to tarnish some board member's CV. But it's going to make a bunch of Canadian's a lot thinner!
https://www.science.org/content/blog-post/novo-nordisk-s-canadian-mistake
https://science.slashdot.org/story/25/06/16/1438211/novo-nordisk-loses-canadian-patent-protection-for-blockbuster-diabetes-drug-over-unpaid-450-fee
no subject
On a separate note, can't comprehend how Canada can be the second largest market for that shit. We aren't that fat! Or maybe it's my Quebec prospective, idk
no subject
Oh, yeah, we can have metabolic troubles of our own. Not simply over-eating either, but accumulating body fat regardless of our choices and intentions.
no subject
There's also the diabetes origin of the drug.
no subject
It's possible that the diabetic drug side of it makes it the second largest market, I don't know.
no subject
no subject
I wonder if they'll jack up the price in the USA to make up the diff. It wouldn't be out of character.
no subject
no subject
Someone really, really screwed up!
no subject
Somebody's head is going to roll. :o :o :o
Hugs, Jon
no subject
Most definitely!
no subject
They will pick a peon. :o
no subject
Yeah, sacrifice someone who doesn't earn 6-7 digits.
no subject